Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new. Long before the rise of modern...
04
Jun
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No Delays. In early-phase clin...
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the rise of natural products, includi...
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in clinical trials and the use of...
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agilex Biolabs, we understand the...
By Kim Salvatore, Head of Client and Operational Services The bioanalytical and drug development industry is at the forefront o...
There’s a great opportunity for Australian SME’s to take advantage of a well-deserved subsidy! Agilex Biolabs is thrilled t...
Research shows that Biotechnology companies have been facing significant challenges – with continual declines in deal making act...
By Dr. Kurt Sales, CSO Introduction Immunological assays are essential in drug development, especially for immunomodulatory...
By Dr. Kurt Sales, CSO Peripheral Blood Mononuclear Cells (PBMC) are critical for the pharmacodynamic assessment of new drug pr...
